Many studies show that omalizumab is effective for Allergic bronchopulmonary aspergillosis (ABPA) and that it can help many patients, but no regulatory authority has not approved it. Let’s take a look at some of these studies.
1. 102 cases from 30 published literature were analyzed and it said that omalizumab therapy in ABPA not only provided a reduction in serum IgE, exacerbation rates, and steroid requirement but also showed reduced asthma symptoms and improved pulmonary functions in patients with ABPA.
2. Another study included 18 patients who had ABPA along with cystic fibrosis and omalizumab was able to treat it with less side effects compared to long-term corticosteroids.
3. This third study we found said that omalizumab was effective and safe to treat patients with ABPA (they also had a chronic bacterial infection in the airways). The only side effect was injection site reactions.
Omalizumab seems to be a good alternative or an additional treatment option for ABPA.